Pharmaceutical Industry observers may have recently read about how biopharmaceutical companies and insurers are working together to implement new approaches to paying for medicines, including through results-based contracts (RBCs), which link reimbursement to real patient outcomes, writes Michelle Drozd, a deputy vice president in the policy and research department at Pharmaceutical Research and Manufacturers of America (PhRMA), on The Catalyst blog. 11 January 2018